These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

166 related articles for article (PubMed ID: 15125489)

  • 1. The potential role of angiotensin-converting enzyme inhibition in peripheral arterial disease.
    Hirsch AT; Duprez D
    Vasc Med; 2003 Nov; 8(4):273-8. PubMed ID: 15125489
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Peripheral artery disease: potential role of ACE-inhibitor therapy.
    Coppola G; Romano G; Corrado E; Grisanti RM; Novo S
    Vasc Health Risk Manag; 2008; 4(6):1179-87. PubMed ID: 19337531
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effects of renin-angiotensin system inhibition on end-organ protection: can we do better?
    Weir MR
    Clin Ther; 2007 Sep; 29(9):1803-24. PubMed ID: 18035185
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Should all patients with peripheral arterial disease be treated with an angiotensin-converting enzyme inhibitor?
    Al-Omran M; Lindsay TF
    Can J Cardiol; 2005 Feb; 21(2):189-93. PubMed ID: 15729421
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Manipulation of the renin angiotensin system in peripheral arterial disease.
    Hobbs SD; Thomas ME; Bradbury AW
    Eur J Vasc Endovasc Surg; 2004 Dec; 28(6):573-82. PubMed ID: 15531190
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Optimal medical management of peripheral arterial disease.
    Rice TW; Lumsden AB
    Vasc Endovascular Surg; 2006; 40(4):312-27. PubMed ID: 16959725
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Should an angiotensin-converting enzyme inhibitor be standard therapy for patients with atherosclerotic disease?
    O'Keefe JH; Wetzel M; Moe RR; Bronsnahan K; Lavie CJ
    J Am Coll Cardiol; 2001 Jan; 37(1):1-8. PubMed ID: 11153722
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Hypertension mega-trials with cardiovascular end points: effect of angiotensin-converting enzyme inhibitors and angiotensin receptor blockers.
    Kjeldsen SE; Julius S
    Am Heart J; 2004 Nov; 148(5):747-54. PubMed ID: 15523303
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Pharmacotherapy of arteriosclerosis and its complications. Effect of ACE inhibitors and HMG-CoA-reductase inhibitors].
    Tschudi MR; Noll G; Lüscher TP
    Schweiz Med Wochenschr; 1997 Apr; 127(15):636-49. PubMed ID: 9198890
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The role of the renin-angiotensin system in vascular health: use of ACE inhibition to improve vascular function.
    Izzo JL
    Heart Dis; 2000; 2(5):380-3. PubMed ID: 11728286
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Angiotensin antagonism in coronary artery disease: results after coronary revascularisation.
    Ribichini F; Ferrero V; Rognoni A; Vacca G; Vassanelli C
    Drugs; 2005; 65(8):1073-96. PubMed ID: 15907144
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effect of the renin--angiotensin system on the vessel wall: using ACE inhibition to improve endothelial function.
    Neutel JM
    J Hum Hypertens; 2004 Sep; 18(9):599-606. PubMed ID: 15190263
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Endothelial function, fibrinolysis, and angiotensin-converting enzyme inhibition.
    Vaughan DE
    Clin Cardiol; 1997 Nov; 20(11 Suppl 2):II-34-7. PubMed ID: 9422850
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Modulating atherosclerosis through inhibition or blockade of angiotensin.
    Rosenson RS
    Clin Cardiol; 2003 Jul; 26(7):305-11. PubMed ID: 12862295
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Atherosclerotic risk factor control in patients with peripheral arterial disease.
    Rehring TF; Sandhoff BG; Stolcpart RS; Merenich JA; Hollis HW
    J Vasc Surg; 2005 May; 41(5):816-22. PubMed ID: 15886666
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The use of secondary medical prevention after primary vascular reconstruction: studies on usage and effectiveness.
    Høgh AL
    Dan Med J; 2012 Sep; 59(9):B4514. PubMed ID: 22951205
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Recent changes in the landscape of combination RAS blockade.
    Epstein BJ; Smith SM; Choksi R
    Expert Rev Cardiovasc Ther; 2009 Nov; 7(11):1373-84. PubMed ID: 19900020
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Peripheral arterial disease: a review of disease awareness and management.
    Watson K; Watson BD; Pater KS
    Am J Geriatr Pharmacother; 2006 Dec; 4(4):365-79. PubMed ID: 17296541
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Angiotensin converting enzyme (ACE) and HydroxyMethylGlutaryl-CoA (HMG-CoA) reductase inhibitors in the forefront of pharmacology of endothelium.
    Chłopicki S; Gryglewski RJ
    Pharmacol Rep; 2005; 57 Suppl():86-96. PubMed ID: 16415489
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Angiotensin-converting enzyme inhibitors and coronary artery disease.
    Sayer JW; Timmis AD
    Cardiovasc Drugs Ther; 1996 Nov; 10 Suppl 2():631-7. PubMed ID: 9115957
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.